Recruiting

Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia

his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide

I'm interested View official listing

ClinicalTrials.gov IDNCT07349277

PhaseNot Applicable

Enrollment120

SponsorAmmar Jassim Abed

Age18 Years – 45 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Preeclampsia, Gestational Hypertension, Hypertensive Disorders of Pregnancy

About this study

Primary outcomes

Serum sFlt-1 concentration (At enrollment (20-36 weeks of gestation))
Serum PlGF concentration (At enrollment (20-36 weeks of gestation))
sFlt-1/PlGF ratio (At enrollment (20-36 weeks of gestation))
Serum Osteoprotegerin (OPG) concentration (At enrollment (20-36 weeks of gestation))
Serum sENG(Souble Endoglin) concentration (At enrollment (20-36 weeks of gestation))

Eligibility information

IInclusion Criteria: * Pregnant women between 20 and 36 weeks of gestation * Age between 18 and 45 years * Attending the antenatal clinic at the study site Exclusion Criteria: * Chronic hypertension * Renal disease * Diabetes mellitus * Multiple gestations * Autoimmune disorders

Study locations

Bint Al Huda Maternity Hospital, Nasiriyah, Dhi Qar 64001 Iraq

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-04.